Delving into the Latest Updates on ImmuneMed, Inc. with Synapse

Overview

Basic Info

Introduction

ImmuneMed, Inc. is a company that specializes in the development of anti-virus substances and conducts various health-related research. The company was established in 2000 by Yoon-Won Kim and is based in Chuncheon, South Korea.

Tags

Digestive System Disorders

Immune System Diseases

Endocrinology and Metabolic Disease

Chemical drugs

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	2
Endocrinology and Metabolic Disease	1
Infectious Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Chemical drugs	2
Monoclonal antibody	1

Top 5 Target	Count

vimentin	1

This is a multicenter, randomized, double-blind, parallel group, 48-week follow-up, Phase IIa clinical study. This study has been designed to evaluate the change in HBsAg (log10 IU/mL) after administration of hzVSF-v13 50 mg/dose and hzVSF-v13 200 mg/dose in combination with an oral antiviral agent (Tenofovir or entecavir, including salt-free or salt-modifying drugs) compared to an oral antiviral agent in combination with a placebo (normal saline) in patients with chronic hepatitis B who are stably receiving an oral antiviral agent (Tenofovir or entecavir, including salt-free or salt-modifying drugs) for at least 24 weeks.

Start Date11 Jan 2022

Sponsor / Collaborator

ImmuneMed, Inc.

NCT04679350 / TerminatedPhase 2

A Multi Center, Randomized, Double-blind, Parallel Design, Phase 2 Study to Evaluate the Efficacy and Safety of hzVSFv13 Compared to Standard of Care After Intravenous(IV) Administration With Add-on Standard of Care in COVID-19 Moderate to Severe Patients

To explore the efficacy and confirm the safety of the concomitant administration of the standard of care and hzVSF-v13 in patients with COVID-19 infection

Start Date18 Mar 2021

Sponsor / Collaborator

ImmuneMed, Inc.

100 Clinical Results associated with ImmuneMed, Inc.

Login to view more data

0 Patents (Medical) associated with ImmuneMed, Inc.

Login to view more data

5

Literatures (Medical) associated with ImmuneMed, Inc.

CellsQ3 · BIOLOGY

Combination Treatment with the Vimentin-Targeting Antibody hzVSF and Tenofovir Suppresses Woodchuck Hepatitis Virus Infection in Woodchucks

Q3 · BIOLOGY

ArticleOA

Author: Li, Bin ; Huang, Xu ; Lee, Kyoung-pil ; Park, Sungman ; Kim, Yoon-Won ; Korolowicz, Kyle E. ; Suresh, Manasa ; Kallakury, Bhaskar V. ; Yon, Changsuek ; Menne, Stephan

Current treatment options for patients infected with hepatitis B virus (HBV) are suboptimal, because the approved drugs rarely induce cure due to the persistence of the viral DNA genome in the nucleus of infected hepatocytes, and are associated with either severe side effects (pegylated interferon-alpha) or require life-long administration (nucleos(t)ide analogs). We report here the evaluation of the safety and therapeutic efficacy of a novel, humanized antibody (hzVSF) in the woodchuck model of HBV infection. hzVSF has been shown to act as a viral entry inhibitor, most likely by suppressing vimentin-mediated endocytosis of virions. Targeting the increased vimentin expression on liver cells by hzVSF after infection with HBV or woodchuck hepatitis virus (WHV) was demonstrated initially. Thereafter, hzVSF safety was assessed in eight woodchucks naïve for WHV infection. Antiviral efficacy of hzVSF was evaluated subsequently in 24 chronic WHV carrier woodchucks by monotreatment with three ascending doses and in combination with tenofovir alafenamide fumarate (TAF). Consistent with the proposed blocking of WHV reinfection, intravenous hzVSF administration for 12 weeks resulted in a modest but transient reduction of viral replication and associated liver inflammation. In combination with oral TAF dosing, the antiviral effect of hzVSF was enhanced and sustained in half of the woodchucks with an antibody response to viral proteins. Thus, hzVSF safely but modestly alters chronic WHV infection in woodchucks; however, as a combination partner to TAF, its antiviral efficacy is markedly increased. The results of this preclinical study support future evaluation of this novel anti-HBV drug in patients.

JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH

Serological Diagnosis of Acute Scrub Typhus in Southern India: Evaluation of InBios Scrub Typhus Detect IgM Rapid Test and Comparison with other Serological Tests

Article

Author: Pradeep, Jothimani ; Park, Sungman ; Kim, Seung-Han ; Kim, Yoon-Won ; Kim, Young Jin ; Stephen, Selvaraj ; Anitharaj, Velmurugan ; Kim, Eun-Ye

INTRODUCTIONScrub Typhus (ST) is being reported from different parts of India in the recent past. However, the diagnosis and confirmation of ST cases require specific serological and molecular diagnostic tests. Both rapid and conventional ELISA tests need to be properly evaluated.AIMEvaluation of a new ST IgM Immunochromatography (ICT) test kit (InBios Scrub Typhus Detect IgM Rapid Test) and compare it with another rapid kit, conventional ELISA kit and Weil-Felix (WF) test.MATERIALS AND METHODSThis prospective study was carried out in Mahatma Gandhi Medical College and Research Institute, Puducherry, during November 2015 to June 2016. Clinically suspected 220 ST patients were examined by a new kit, InBios Scrub Typhus Detect IgM Rapid Test, taking the conventional InBios Scrub Typhus Detect IgM ELISA as reference. Additional comparison was made with ImmuneMed Scrub Typhus Rapid, and WF test (single OXK titers ≥1:320). Statistical analysis was performed (Chi-square, Spearman's correlation and Kappa) using IBM SPSS Statistics 17 for Windows (SPSS Inc; Chicago, USA).RESULTSPercentage Sensitivity, Specificity, Positive Predictive and Negative Predictive Values for InBios, ImmuneMed and WF were 99.25, 93.02, 95.68, 98.77; 94.87, 94.19, 96.21, 92.05 and 50.38, 95.51, 94.29, 56.67 respectively. A total of 134 patients were positive in reference standard InBios IgM ELISA.CONCLUSIONThis new rapid ST IgM kit validated for the first time in India, showed good sensitivity and specificity. As a Point-of-Care (PoC) test, the kit would be helpful in both urban and remote rural parts of India.

Journal of vector borne diseases

Evaluation of ImmuneMed scrub typhus rapid test kit, for diagnosis of scrub typhus.

Article

Author: Pradeep, Jothimani ; Stephen, Selvaraj ; Kim, Yoon-Won ; Kim, Eun-Ye ; Kim, Seung-Han ; Park, Sungman ; Kim, Min-Woo ; Kim, Young Jin

100 Deals associated with ImmuneMed, Inc.

Login to view more data

100 Translational Medicine associated with ImmuneMed, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

1

Phase 2 Clinical

Other

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Burfiralimab ( vimentin )	Rheumatoid Arthritis More	Phase 2
cGvHD(ImmuneMed)	Graft vs Host Disease More	Preclinical
PDAC(ImmuneMed)	Pancreatic Ductal Adenocarcinoma More	Preclinical
IM-02	Viremia More	Pending
IMV-01	Dengue More	Pending